Erratum: Drugs, their targets and the nature and number of drug targets (Nature Reviews Drug Discovery (2006) vol. 5 (821-827) 10.1038/nrd2132);Drugs, their targets and the nature and number of drug targets

Nature Reviews Drug Discovery

Volumn 5, Issue 10, 2006, Pages 821-834

  Imming, Peter ^a   Sinning, Christian ^a   Meyer, Achim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOROLFINE; CHLORAMPHENICOL; DISULFIRAM; DUTASTERIDE; ENTACAPONE; EXEMESTANE; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; ISONIAZID; LEFLUNOMIDE; MESALAZINE; MILTEFOSINE; MOCLOBEMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITISINONE; PARACETAMOL; PEMETREXED; PHENPROCOUMON; PROGUANIL; PROPYLTHIOURACIL; TERBINAFINE; THIOURACIL DERIVATIVE; TRANYLCYPROMINE; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN; ZILEUTON;

ALLOSTERISM; ARTICLE; CATALOGING DATABASE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; GENE SEQUENCE; GENETIC CODE; HUMAN; KNOCKOUT MOUSE; MOLECULAR INTERACTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FAMILY;

EID: 33749234216     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2261     Document Type: Erratum

References (301)

1. Drews, J. & Ryser, S. The role of innovation in drug development. Nature Biotechnol. 15, 1318-1319 (1997).
2. Burgess, J. & Golden, J. Cracking the druggable genome. Bio-IT World [online], (2002).
3. Hopkins, A. & Groom, C. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
4. Saunders, J. G-protein-coupled receptors in drug discovery. Bioorg. Med. Chem. Lett. 15, 3653 (2005)
5. Zambrowicz, B. P. & Sands. A. T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev. Drug Discov. 2, 38-51 (2003).
6. Jonker, D. M., Visser, S. A. G., van der Graaf, P. H., Voskuyl, R. A. & Danhof, M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Therapeut. 106, 1-18 (2005).
7. Agnati, L. F., Fuxe, K. & Ferré, S. How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends Biochem. Sci. 30, 188-193 (2005).
8. Heien, M. L. A. V. et al. Real-time measurement of dopamine fluctuations after cocaine in the brain of behaving rats. Proc. Natl Acad. Sci. USA 102, 10023-10028 (2005).
9. Mitcheson, J. S., Chen, J. & Sanguinetti, M. C. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 115, 229-240 (2000).
10. Hyman, S. E. & Fenton, W. S. What are the right targets for psychopharmacology? Science 299, 3 50-351 (2003).
11. Apic, G., Ignjatovic, T., Boyer, S. & Russell, R. B. Illuminating drug discovery with biological pathways. FEBS Lett. 579, 1872-1877 (2005).
12. Schneider, G. Trends in virtual combinatorial library design. Curr. Med. Chem. 9, 2095-2101 (2002).
13. Goodnow, R. Jr., Guba, W. & Haap, W. Library design practices for success in lead generation with small molecule libraries. Comb. Chem. High Throughput Screen. 6, 649-660 (2003).
14. Hendlich, M., Bergner. A., Gunther, J. & Klebe, G. Relibase: Design and development of a database for comprehensive analysis of protein-ligand interactions. J. Mol. Biol. 326, 607-620 (2003).
15. Gohlke, H. & Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed. Engl. 41, 2644-2676 (2002).
16. Schwabe, U. ATC-Code (Wissenschaftliches Institut der AOK, Bonn, Germany, 1995).
17. Imming, P. et al. A classification of drug substances according to their mechanism of action. Pharmazie 59, 579-589 (2004).
18. Swinney, D. C. Biochemical mechanisms of drug action: What does it take for success? Nature Rev. Drug Discov. 3, 801-808 (2004).
19. World Health Organization. The Essential Medicines List [online], (2002).
20. Approved Drug Products 25th edition and Cumulative Supplement (US Department of Health and Human Services, 2005).
21. Pharmazeutische Zeitung Neue Arzneistoffe [online], (2005).
22. CDER Drug and Biologic Approval Reports [online], (2006).
23. Robertson, J. G. Mechanistic basis of enzyme-targeted drugs. Biochemistry 44, 5561-5571 (2005).
24. Alexander, S. P. H, Mathie, A. & Peters, J. A. TiPS nomenclature supplement. Trends Pharmacol. Sci. 12, 1-146 (2001).
25. Mutschler, E., Geisslinger, G., Kraemer, H. K., Schäfer-Korting, M. Mutschler Arzneimittelwirkungen (Wissenschaftliche, Stuttgart, 2001).
26. Goldberg, N. R. et al. A. Probing conformational changes in neurotransmitter transporters: A structural context. Eur. J. Pharmacol. 479, 3-12 (2003).
27. Saier Jr., M. H. A functional-phylogenetic system for the classification of transport proteins. J. Cell Biochem. Suppl. 32-33, 84-94 (1999).
28. Krishnan, K., Campbell, S., Abdel-Rahman, F., Whaley, S. & Stone, W. L. Cancer chemoprevention drug targets. Curr. Drug Targets 4, 45-54 (2003).
29. Morphy, R. & Rankovic, Z. Designed multiple ligands: An emerging drug discovery paradigm. J. Med. Chem. 48, 6523-6543 (2005).
30. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: Selectively nonselective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353-359 (2004).
31. Law, M. R., Wald, J., Morris, J. K. & Jordan, R. E. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. Br. Med. J. 326, 1427-1431 (2003).
32. Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nature Rev. Drug Discov. 4, 1-7 (2005).
33. Roden, D. M. Antiarrhythmic drugs: Past, present, and future. J. Cardiovasc. Electrophysiol. 14, 1389-1396 (2003).
34. Grosser, T., Fries, S. & FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
35. Sozzani, S. et al. Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. J. Biol. Chem. 267, 20481-20488 (1992).
36. Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B. & Prossnitz, E. R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625-1630 (2005).
37. Chulia, S. et al. Relationships between structure and vascular activity in a series of benzylisoquinolines. Br. J. Pharmacol. 122, 409-416 (1997).
38. Frantz, S. Playing dirty. Nature 437, 942-943 (2005).
39. Petersen, E. N. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 369, 7-13 (1992).
40. Baker, G. B., Coutts, R. T., McKenna, K. F. & Sherry-McKenna, R. L. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: A review. J. Psychiatry Neurosci. 17, 206-214 (1992).
41. Haefely, W. et al. Pharmacology of moclobemide. Clin. Neuropharmacol. 16 (Suppl 2), 8-18 (1993).
42. Garavito, R. M., Malkowski, M. G. & DeWitt, D. L. The structures of prostaglandin endoperoxide H synthases-1 and-2. Prostaglandins Other Lipid Mediat. 68-69, 129-152 (2002).
43. Smith, W. L. & Song, I. The enzymology of prostaglandin endoperoxide H synthases-1 and-2. Prostaglandins Other Lipid Mediat. 68-69, 115-28 (2002).
44. Hogestatt, E. D. et al. Conversion ofacetaminophen to the bioactive N-acyl phenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem. 280, 31405-31412 (2005).
45. Mann, K. G. The challenge of regulating anticoagulant drugs: Focus on warfarin. Am. Heart J. 149 (Suppl 1), 36-42 (2005).
46. Miller, R. W. Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer. Semin. Oncol. 30 (4 Suppl 14), 3-11 (2003).
47. Maertens, J. A. History of the development of azole derivatives. Clin. Microbiol. Infect. 10 (Suppl 1), 1-10 (2004).
48. Klotz, U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur. J. Clin. Pharmacol. 56, 353-362 (2000).
49. Parnes, S. M. The role of leukotriene inhibitors in patients with paranasal sinus disease. Curr. Opin. Otolaryngol. Head Neck. Surg. 11, 184-191 (2003).
50. Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905-917 (2005).
51. Allison, A. C. & Eugui, E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47, 85-118 (2000).
52. Stancu, C. & Sima, A. Statins: Mechanism of action and effects. J. Cell. Mol. Med. 5, 378-387 (2001).
53. Bull, H. G. et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: Enzyme-catalyzed formation of NADP-Dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118, 2359-2365 (1996).
54. Matthews, D. A. et al. Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J. Biol. Chem. 260, 381-391 (1985).
55. Goldman, I. D. & Zhao, R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin. Oncol. 29 (6 Suppl 18), 3-17 (2002).
56. Anderson, A. C. Targeting DHFR in parasitic protozoa. Drug Discov. Today 10, 121-128 (2005).
57. Fox, R. I. Mechanism of action of leflunomide in rheumatoid arthritis. J. Rheumatol. Suppl. 53, 20-26 (1998).
58. Heath, R. J., White. S. W. & Rock, C. O. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58, 695-703 (2002).
59. Ryder, N. S. The mechanism of action of terbinafine. Clin. Exp. Dermatol. 14, 98-100 (1989).
60. Barrett-Bee, K. & Dixon, G. Ergosterol biosynthesis inhibition: A target for antifungal agents. Acta Biochim. Pol. 42, 465-479 (1995).
61. Borges, F., Fernandes, E. & Roleira, F. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. 9, 195-217 (2002).
62. Brownlee, J. M., Johnson-Winters, K., Harrison, D. H. & Moran, G. R. Structure of the ferrous form of (4-hydroxyphenyl)pyruvate dioxygenase from Streptomyces avermitilis in complex with the therapeutic herbicide, NTBC. Biochemistry 43, 6370-6377 (2004).
63. Yarbro, J. W. Mechanism of action of hydroxyurea. Semin. Oncol. 19 (Suppl 9), 1-10 (1992).
64. Hofmann, J. Modulation of protein kinase C in antitumor treatment. Rev. Physiol. Biochem. Pharmacol. 142, 1-96 (2001).
65. Jendrossek, V. & Handrick, R. Membrane targeted anticancer drugs: Potent inducers of apoptosis and putative radiosensitisers. Curr. Med. Chem. Anti-Canc. Agents 3, 343-353 (2003).
66. Atkins, M., Jones, C. A. & Kirkpatrick P. Sunitinib maleate. Nature Rev. Drug Discov. 5, 279-280 (2006).
67. Schlünzen, F. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814-821 (2001).
68. Mannisto, P. T. et al. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 39, 291-350 (1992).
69. Komo, K., Oizumi, K. & Oka, S. Mode of action of rifampin on mycobacteria. Am. Rev. Respir. Dis. 107, 1006-1012 (1973).
70. Painter, G. R., Almond, M. R., Mao, S. & Liotta, D. C. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Curr. Top. Med. Chem. 4, 1035-1044 (2004).
71. Zapor, M. J., Cozza, K. L., Wynn, G. H., Wortmann, G. W. & Armstrong, S. C. Antiretrovirals, Part II: Focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 45, 524-535 (2004).
72. Bell, C., Matthews, G. V. & Nelson, M. R. Nonnucleoside reverse transcriptase inhibitors - an overview. Int. J. STD AIDS 14, 71-77 (2003).
73. Young, S. D. et al. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39, 2602-2605 (1995).
74. Earnshaw, D. L., Bacon, T. H., Darlison, S. J., Edmonds, K., Perkins, R. M. & Vere Hodge, R. A. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36, 2747-2757 (1992).
75. Walther, M. M., Trahan, E. E., Cooper, M., Venzon, D. & Linehan, W. M. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. J. Urol. 152, 1599-1602 (1994).
76. Gurvich, N., Tsygankova, O. M., Meinkoth, J. L. & Klein, P. S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64, 1079-1086 (2004).
77. Angehagen, M., Ben-Menachem, E., Ronnback, L. & Hansson, E. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem. Res. 28, 333-340 (2003).
78. Buchdunger, E. et al. ABL protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145 (2000).
79. Minna, J. D. & Dowell, J. Erlotinib hydrochloride. Nature Rev. Drug Discov. 4, S14-S15 (2005).
80. Yoon, H. J. et al. Crystallization and preliminary X-ray crystallographic analysis of UDP-N-acetylglucosamine enolpyruvyl transferase from Haemophilus influenzae in complex with UDP-N-acetylglucosamine and fosfomycin. Mol. Cell 19, 398-401 (2005).
81. El Zoeiby, A., Sanschagrin, F. & Levesque, R. C. Structure and function of the Mur enzymes: Development of novel inhibitors. Mol. Microbiol. 47, 1-12 (2003).
82. Goto, M. et al. M. Structural determinants for branched-chain aminotransferase isozyme specific inhibition by the anticonvulsant drug gabapentin. J. Biol. Chem. 280, 37246-37256 (2005).
83. Adams, J. The proteasome: A suitable antineoplastic target. Nature Rev. Cancer 4, 349-360 (2004).
84. Sugimoto, H., Ogura, H., Arai, Y., Limura, Y. & Yamanishi, Y. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn, J. Pharmacol. 89, 7-20 (2002).
85. Kwong, T. C. Organophosphate pesticides: Biochemistry and clinical toxicology. Ther. Drug Monit. 24, 144-149 (2002).
86. Fisone, G., Borgkvist, A. & Usiello, A. Caffeine as a psychomotor stimulant: Mechanism of action. Cell. Mol. Life Sci. 61, 857-872 (2004).
87. Honerjager, P. & Nawrath, H. Pharmacology of bipyridine phosphodiesterase III inhibitors. Eur. J. Anaesthesiol. Suppl. 5, 7-14 (1992).
88. Kaneda, T., Takeuchi, Y., Matsui, H., Shimizu, K., Urakawa, N. & Nakajyo, S. Inhibitory mechanism of papaverine on carbachol-induced contraction in bovine trachea. J. Pharmacol. Sci. 98, 275-282 (2005).
89. Corbin, J. D. & Francis, S. H. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J. Androl. 24 (Suppl 6), 38-41 (2003).
90. Beutler, A. S., Li, S., Nicol, R. & Walsh, M. J. Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 76, 3107-3115 (2005).
91. Calfee, D. P. & Hayden, F. G. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 56, 537-553 (1998).
92. Krasikov, V. V., Karelov, D. V. & Firsov, L. M. alpha-Glucosidases. Biochemistry (Mosc). 66, 267-281 (2001).
93. Guerciolini, R. Mode of action of orlistat. Int. J. Obes Relat. Metab. Disord. 21 (Suppl 3), 12-23 (1997).
94. Wynn, G. H., Zapor, M. J., Smith, B. H., Wortmann, G., Oesterheld, J. R., Armstrong, S. C. & Cozza, K. L. Antiretrovirals, part 1: Overview, history, and focus on protease inhibitors. Psychosomatics 45, 262-270 (2004).
95. Wegner, J. Biochemistry of serine protease inhibitors and their mechanisms of action: A review. J. Extra. Corpor. Technol. 35, 326-338 (2003).
96. Konaklieva, M. I. β-lactams as inhibitors of serine enzymes. Curr. Med. Chem. Anti-Infect. Agents 1, 215-238 (2002).
97. Nicolau, K. C., Boddy C. N. C., Brase, S. & Winssinger, N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem., Int. Ed. Engl. 38, 2096-2152 (1999).
98. Matagne, A., Dubus, A., Galleni, M. & Frere, J. M. The β-lactamase cycle. Nat. Prod. Rep. 16, 1-19 (1999).
99. Hirsh, J., Raschke, R., Warkentin, T. E., Dalen, J. E., Deykin, D. & Poller, L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 108 (Suppl. 4), 258-275 (1995).
100. Nader, H. B., Lopes, C. C., Rocha, H. A., Santos, E. A. & Dietrich, C. P. Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr. Pharm. Des. 10, 951-966 (2004).
101. Wolvekamp, M. C. & de Bruin, R. W. Diamine oxidase: An overview of historical, biochemical and functional aspects. Dig. Dis. 12, 2-14 (1994).
102. Weitz, J. I., Stewart, R. J. & Fredenburgh, J. C. Mechanism of action of plasminogen activators Thromb. Haemost. 82, 974-982 (1999).
103. Bajaj, A. P. & Castellino, F. J. Activation of human plasminogen by equimolar levels of streptokinase. J. Biol. Chem. 252, 492-498 (1977).
104. Spronk, H. M., Govers-Riemslag, J. W. & ten Cate, H. The blood coagulation system as a molecular machine. Bioessays 25, 1220-1228 (2003).
105. Bauer, K. A. Fondaparinux sodium: A selective inhibitor of factor Xa. Am. J. Health Syst. Pharm. 58 (Suppl 2), 14-17 (2001).
106. Nemec, K, & Schubert-Zsilavecz, M. From teprotide to captopril. Rational design of ACE inhibitors. Pharm. Unserer Zeit 32, 11-16 (2003).
107. Pastel, D. A. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination. Clin. Pharm. 5, 719-736 (1986).
108. Bondeson, J. The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen. Pharmacol. 29, 127-150 (1997).
109. Adnane, L., Trail, P. A., Taylor, I., Wilhelm, S. M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407, 597-612 (2005).
110. De la Baume, S., Brion, F., Dam-Trung-Tuong, M. & Schwartz, J. C. Evaluation of enkephalinase inhibition in the living mouse, using [3H]acetorphan as a probe. J. Pharmacol. Exp. Ther. 247, 653-660 (1988).
111. Reynolds, N. J. & Al-Daraji, W. I. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin. Exp. Dermatol. 27, 555-561 (2002).
112. 2+-dependent phosphatases. J. Mol. Biol. 320, 1087-1094 (2002).
113. Spiegelberg, B. D, Dela Cruz, J., Law, T. H & York, J. D. Alteration of lithium pharmacology through manipulation of phosphoadenosine phosphate metabolism. J. Biol. Chem. 280, 5400-5405 (2005).
114. Tiede, I. et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 + T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
115. El Ghachi, M., Bouhss, A., Blanot, D. & Mengin-Lecreulx, D. The bacA gene of Escherichia coli encodes an undecaprenyl pyrophosphate phosphatase activity. J. Biol. Chem. 279, 30106-30113 (2004).
116. Bartholini, G. & Pletscher, A. Decarboxylase inhibitors. Pharmacol. Ther. [B]. 1, 407-421 (1975).
117. Supuran, C. T., Scozzafava, A. & Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 23, 146-189 (2003).
118. Sonneville, A. Hypostamine (tritoqualine), a synthetic reference antihistaminic. Allerg. Immunol. (Paris) 20, 365-368 (1988).
119. Huang, Y., Pledgie, A., Casero, R. A. Jr. & Davidson, N.E. Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs 16, 229-241 (2005).
120. Chen, Z. et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc. Natl Acad. Sci. USA 102, 12159-12164 (2005).
121. Thatcher, G. R., Nicolescu, A. C., Bennett, B M. & Toader, V. Nitrates and NO release: Contemporary aspects in biological and medicinal chemistry. Free Rad. Biol. Medic. 37, 1122-1143 (2004).
122. Ignarro, L. J. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc. Natl Acad. Sci. USA 99, 7816-7817 (2002).
123. Kukovetz, W. R. & Holzmann, S. Cyclic GMP as the mediator of molsidomine-induced vasodilatation. Eur. J. Pharmacol. 122, 103-109 (1986).
124. Fenn, T. D., Stamper, G. F., Morollo, A. A. & Ringe, D. A side reaction of alanine racemase: Transamination of cycloserine. Biochemistry 42, 5775-5783 (2003).
125. Drlica, K. & Malik, M. Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem. 3, 249-282 (2003).
126. Pizzolato, J. F. & Saltz, L. B. The camptothecins. Lancet 361, 2235-2242 (2003).
127. Meresse, P., Dechaux, E., Monneret, C. & Bertounesque, E. Etoposide: discovery and medicinal chemistry. Curr. Med. Chem. 11, 2443-2466 (2004).
128. Polak-Wyss, A., Lengsfeld, H., Oesterhelt, G. Effect of oxiconazole and Ro 14-4767/002 on sterol pattern in Candida albicans. Sabouraudia 23, 433-441 (1985).
129. Achari, A. et al. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nature Struct. Biol. 4, 490-497 (1997).
130. Langley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev. Cancer 3, 330-338 (2003).
131. Gilli, R., Lopez, C., Sari, J. C. & Briand, C. Thermodynamic study of the interaction of methotrexate, its metabolites, and new antifolates with thymidylate synthase: Influence of FdUMP. Biochem. Pharmacol. 40, 2241-2246 (1990).
132. Su, J. G., Mansour, J. M. & Mansour, T. E. Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni. Mol. Biochem. Parasitol. 81, 171-178 (1996).
133. Sehgal, S. N. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant. Proc. 35 (Suppl 3), 7-14 (2003).
134. Foley, M. & Tilley, L. Quinoline antimalarials: Mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79, 55-87 (1998).
135. Denning, D. W. Echinocandin antifungal drugs. Lancet 362, 1142-1151 (2003).
136. McCormack, P. L. & Goa, K. L. Miglustat. Drugs 63, 2427-2434 (2003).
137. Graham, M. L. Pegaspargase: A review of clinical studies. Adv. Drug Deliv. Rev. 55, 1293-1302 (2003).
138. Pea, F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib. Nephrol. 147, 35-46 (2005).
139. Dressler, D. & Adib Saberi, F. Botulinum toxin: Mechanisms of action. Eur. Neurol. 53, 3-9 (2005).
140. Czapinski, P., Blaszczyk, B. & Czuczwar, S. J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 5, 3-14 (2005).
141. A receptor subtypes: Any clues to the mechanism of benzodiazepine dependence? Curr. Opin. Pharmacol. 5, 47-52 (2005).
142. Hoffman, E. J. & Warren, E. W. Flumazenil: A benzodiazepine antagonist. Clin. Pharm. 12, 641-656 (1993).
143. Martin, R. J., Robertson, A. P. & Bjorn, H. Target sites of anthelmintics. Parasitology 114 (Suppl), 111-124 (1997).
144. Martin, R. J. Modes of action of anthelmintic drugs. Vet. J. 154, 11-34 (1997).
145. McManus, M. C. Neuromuscular blockers in surgery and intensive care, Part 1. Am. J. Health Syst. Pharm. 58, 2287-2299 (2001).
146. Bowman, W. C. Neuromuscular block. Br. J. Pharmacol. 147 S1, 277-286 (2006).
147. Samochocki, M. et al. Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurol. Scand. Suppl. 176, 68-73 (2000).
148. Rogawski, M. A. & Wenk, G. L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. C. N. S. Drug Rev. (Fall) 9, 275-308 (2003).
149. Dahchour, A. & De Witte, P. Ethanol and amino acids in the central nervous system: Assessment of the pharmacological actions of acamprosate. Prog. Neurobiol. 60, 343-362 (2000).
150. Kress, H. G. Mechanisms of action of ketamine. Anaesthesist 46 (Suppl. 1), 8-19 (1997).
151. Gautam, D. et al. Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol. Pharmacol. 66, 260-267 (2004).
152. Eglen, R. M., Choppin, A. & Watson, N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol. Sci. 22, 409-414 (2001)
153. Pitschner, H. F. et al. Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol. Sci. Suppl. 92-96 (1989).
154. Hegde, S. S. et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol. 120, 1409-1418 (1997).
155. Fredholm, B. B., Chen. J. F., Masino, S. A. & Vaugeois, J. M. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 45, 385-412 (2005).
156. 1 adenosine receptors. J. Nat. Prod. 65, 1479-1485 (2002).
157. Fisone, G., Borgkvist, A. & Usiello, A. Caffeine as a psychomotor stimulant: Mechanism of action. Cell. Mol. Life Sci. 61, 857-872 (2004).
158. Ruffolo, R. R., Bondinell, W. Jr. & Hieble, J. P. α- and β-adrenoceptors: From the gene to the clinic. 2, Structure-activity relationships and therapeutic applications. J. Med. Chem. 38, 3681-3716 (1995).
159. Hieble, J. P., Bondinell, W. & Ruffolo, R. R. From the gene to the clinic. 1. Molecular biology and adrenoceptor classification. J. Med. Chem. 38, 3415-3444 (1995).
160. Silberstein, S. D. The pharmacology of ergotamine and dihydroergotamine. Headache 37 (Suppl. 1), 15-25 (1997).
161. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 13, 904-12 (2001).
162. Brown, E. M. Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporo. Int. 14 (Suppl 3), 25-34 (2003).
163. Nemeth, E. F. et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCI. J. Pharmacol. Exp. Ther. 308, 627-635 (2004).
164. Grotenhermen, F. Pharmacology of cannabinoids. Neuro. Endocrinol. Lett. 25, 14-23 (2004).
165. Nicosia, S. Pharmacodynamic properties of leukotriene receptor antagonists. Monaldi Arch. Chest Dis. 54, 242-246 (1999)
166. Vallone, D., Picetti, R. & Borrelli, E. Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 24, 125-132 (2000).
167. Clozel, M. et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270, 228-235 (1994).
168. B sites in rat brain. Nature 290, 149-152 (1981).
169. Unson, C. G. Molecular determinants of glucagon receptor signaling. Biopolymers 66, 218-235 (2002).
170. Keating, G. M. Exenatide. Drugs 65, 1681-1692 (2005).
171. 1-antihistamines. N. Engl. J. Med. 351, 2203-2217 (2004).
172. 2-receptor antagonists. Methods Find. Exp. Clin. Pharmacol. 11 (Suppl 1), 87-95 (1989).
173. Pasternak, G. W. Molecular biology of opioid analgesia. J. Pain Symptom. Manage. 29 (Suppl.) S2-S9 (2005).
174. Surratt, C. K. & Adams, W. R. G protein-coupled receptor structural motifs: Relevance to the opioid receptors. Curr. Top. Med. Chem. 5, 315-324 (2005).
175. Diemunsch, P. & Grelot, L. Potential of substance P antagonists as antiemetics. Drugs 60, 533-546 (2000).
176. Narumiya, S., Sugimoto, Y. & Ushikubi, F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79, 1193-1226 (1999).
177. Krauss, A. H. & Woodward, D. F. Update on the mechanism of action of bimatoprost: A review and discussion of new evidence. Surv. Ophthalmol. 49 (Suppl. 1), 5-11 (2004).
178. Herbert, J. M. & Savi, P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin. Vasc. Med. 3, 113-122 (2003).
179. Tunnicliff, G. Molecular basis of buspirone's anxiolytic action. Pharmacol. Toxicol. 69, 149-156 (1991).
180. Ahn, A. H. & Basbaum, A. I. Where do triptans act in the treatment of migraine? Pain 115, 1-4 (2005).
181. Meltzer, H. Y., LI, Z., Kaneda, Y. & Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1159-1172 (2003).
182. Blower, P. R. Granisetron: Relating pharmacology to clinical efficacy. Support Care Cancer 11, 93-100 (2003).
183. Galligan, J. J. & Vanner, S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol. Motil. 17, 643-653 (2005).
184. Chini, B. & Fanelli, F. Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family. Exp. Physiol. 85 Spec. No 59S-66S (2000).
185. Kam, P. C., Williams, S. & Yoong, F. F. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 59, 993-1001 (2004).
186. Kopchick, J. J. Discovery and mechanism of action of pegvisomant. Eur. J. Endocrinol. 148 (Suppl. 2), 21-25 (2003).
187. Zhu, Y. & D'Andrea, A. D. The molecular physiology of erythropoietin and the erythropoietin receptor. Curr. Opin. Hematol. 1, 113-118 (1994).
188. Crawford, J. Neutrophil growth factors. Curr. Hematol. Rep. 1, 95-102 (2002).
189. Sylvester, R. K. Clinical applications of colony-stimulating factors: A historical perspective. Am. J. Health Syst. Pharm. 59, Suppl 2, S6-12 (2002)
190. Fleischmann, R., Stern, R. & Iqbal, I. Anakinra: An inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert. Opin. Biol. Ther. 4, 1333-1344 (2004).
191. Schmidinger, M., Hejna, M. & Zielinski, C. C. Aldesleukin in advanced renal cell carcinoma. Expert. Rev. Anticancer Ther. 4, 957-80 (2004).
192. Cole, P. & Rabasseda, X. The soluble tumor necrosis factor receptor etanercept: A new strategy for the treatment of autoimmune rheumatic disease. Drugs Today (Barc.) 40, 281-324 (2004).
193. Topol, E. J., Byzova, T. V. & Plow, E. F. Platelet GPIIb-IIIa blockers. Lancet 353, 227-231 (1999).
194. Accili, D., Nakae, J. & Flier, J. S. in Diabetes Mellitus - A Fundamental and Clinical Text 3rd edn (eds LeRoith, D., Taylor, S. I. & Olefsky, J. M.) (Lippincott Williams & Wilkins, Philadelphia, 2003).
195. Jiang, G. & Zhang, B. B. Modulation of insulin signalling by insulin sensitizers. Biochem. Soc. Trans. 33, 358-361 (2005)
196. Rogerson, F. M, Brennan, F. E. & Fuller, P. J. Mineralocorticoid receptor binding, structure and function. Mol. Cell. Endocrinol. 217, 203-212 (2004).
197. Necela, B. M. & Cidlowski, J. A. Crystallization of the human glucocorticoid receptor ligand binding domain: A step towards selective glucocorticoids. Trends Pharmacol. Sci. 24, 58-61 (2003).
198. Li, X. & O'Malley, B. W. Unfolding the action of progesterone receptors. J. Biol. Chem. 278, 39261-39264 (2003).
199. Katzenellenbogen, B. S. et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. 74, 279-285 (2000).
200. Levenson, A. S. & Jordan, V. C. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur. J. Cancer 35, 1628-1639 (1999).
201. Gobinet, J., Poujol, N. & Sultan, Ch. Molecular action of androgens. Mol. Cell. Endocrinol. 198, 15-24 (2002).
202. Roy, A. K. et al. Androgen receptor: Structural domains and functional dynamics after ligand-receptor interaction. Ann. N. Y. Acad. Sci. 949, 44-57 (2001).
203. Gao, W., Bohl, C. E. & Dalton, J. T. Chemistry and structural biology of androgen receptor. Chem. Rev. 105(9), 3352-3370 (2005).
204. Neumann, F. The antiandrogen cyproterone acetate: Discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp. Clin. Endocrinol. 102, 1-32 (1994).
205. Carlberg, C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 164, 29-42 (2003)
206. Pinette, K. V., Yee, Y. K., Amegadzie, B. Y. & Nagpal, S. Vitamin D receptor as a drug discovery target. Mini Rev. Med. Chem. 3, 193-204 (2003).
207. Minucci, S. & Ozato, K. Retinoid receptors in transcriptional regulation. Curr. Opin. Genet. Dev. 6, 567-574 (1996).
208. Zwermann, O., Schulte, D. M., Reincke, M. & Beuschlein, F. ACTH 1-24 inhibits proliferation of adrenocortical tumors in vivo. Eur. J. Endocrinol. 153, 435-444 (2005).
209. The Retinoids. Biology, Chemistry and Medicine (eds Mangelsdorf, D. J. et al.) 319-349 (Raven Press, New York, 1994).
210. Czernielewski, J., Michel, S., Bouclier, M., Baker, M. & Hensby, J. C. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J. Eur. Acad. Dermatol. Venereol. 15 (Suppl 3), 5-12 (2001).
211. Duriez, P. Mechanism of actions of statins and fibrates. Therapie 58, 5-14 (2003).
212. Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 (1998).
213. Willson, T. M. et al. The structure-activity relationship between peroxisome proliferator-activated receptor agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665-668 (1996).
214. Brent, G. A. The molecular basis of thyroid hormone action. N. Engl. J. Med. 331, 847-853 (1994).
215. Saier Lab Bioinformatics Group. Transport Classification Database [online], (2006).
216. Schmidt, D. & Elger, C. E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. 5, 627-635 (2004).
217. 2+ channels targets of praziquantel action? Int. J. Parasitol. 35, 1-9 (2005).
218. Moosmang, S., Lenhardt, P., Haider, N., Hofmann, F. & Wegener, J. W. Mouse models to study L-type calcium channel function. Pharmacol. Ther. 106, 347-355 (2005).
219. Triggle, D. J. 1, 4-Dihydropyridines as calcium channel ligands and privileged structures. Cell. Mol. Neurobiol. 23, 293-303 (2003).
220. 2+ channels. Trends Pharmacol. Sci. 19, 108-115 (1998).
221. Meredith, P. A. Lercanidipine: A navel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Investig. Drugs 8, 1043-1062 (1999).
222. Dworkin, R. H. & Kirkpatrick, P. Pregabalin. Nature Rev. Drug Discov. 4, 455-456 (2005).
223. 2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6. 2). J. Cardiovasc. Pharmacol. 42, 161-168 (2003).
224. Gomora, J. C., Daud, A. N., Weiergraber, M. & Perez-Reyes, E. Block
225. Tamargo, J., Caballero, R., Gomez, R., Valenzuela, C. & Delpon, E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 62, 9-33 (2004).
226. Ashcroft, F. M. & Gribble, F. M. New windows on the mechanism of action of K(ATP) channel openers. Trends Pharmacol. Sci. 21, 439-445 (2000).
227. + channel modulating agents on contractions of rat intestinal smooth muscle. Eur. J. Pharmacol. 297, 249-256 (1996).
228. Hu, S., Boettcher, B. R. & Dunning, B. E. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 46 (Suppl. 1), M37-43 (2003).
229. Bryan, J., Crane, A., Vila-Carriles, W. H., Babenko, A. P. & Aguilar-Bryan, L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr. Pharm. Des. 11, 2699-2716 (2005).
230. Kodama, I., Kamiya, K. & Toyama, J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 84, 20R-28R (1999).
231. Roden, D. M. Antiarrhythmic drugs: Past, present, and future. J. Cardiovasc. Electrophysiol. 14, 1389-1396 (2003).
232. Ambrosio, A. F., Soares-Da-Silva, P., Carvalho, C. M. & Carvalho, A. P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 27, 121-130 (2002).
233. Falk, R. H. & Fogel, R. I. Flecainide. J. Cardiovasc. Electrophysiol. 5, 964-981 (1994).
234. Coulter, D. A. Antiepileptic drug cellular mechanisms of action: Where does lamotrigine fit in? J. Child Neurol. 12 (Suppl. 1), S2-S9 (1997).
235. Southam, E. et al. Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo. Eur. J. Pharmacol. 519, 237-245 (2005).
236. + channel voltage-gated peptide by NMR spectroscopy and molecular modeling study. J. Pept. Res. 66, 27-38 (2005).
237. Faber, T. S. & Camm, A. J. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Eur. J. Clin. Pharmacol. 51, 199-208 (1996).
238. White, H. S. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. Headache 45 (Suppl. 1), S48-S56 (2005).
239. Gurvich, N. & Klein, P. S. Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96, 45-66 (2002).
240. Kang, M., Lisk, G., Hollingworth, S., Baylor, S. M. & Desai, S. A. Malaria parasites are rapidly killed by dantrolene derivatives specific for the plasmodial surface anion channel. Mol. Pharmacol. 68, 34-40 (2005).
241. Parness, J. & Palnitkar, S. S. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmatic reticulum. J. Mol. Chem. 270, 18465-18472 (1995).
242. Zygmunt, P. M., Chuang, H., Movahed, P., Julius, D. & Hogestatt, E. D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396, 39-42 (2000).
243. Dutzler, R. The structural basis of CIC chloride channel function. Trends Neurosci. 27, 315-320 (2004).
244. - channels by antiallergic drugs. Biochem. Biophys. Res. Common. 188, 957-963 11992).
245. Cheeseman, C. L., Delany N. S., Woods, D. J. & Wolstenholme, A. J. High-affinity ivermectin binding to recombinant subunits of the Haemonchus contortus glutamate-gated chloride channel. Mol. Biochem. Parasitol. 114, 161-168 (2001).
246. Saier Lab Bioinformatics Group, Transport Classifcation Database, http://www.tcdb.org
247. Gamba, G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol. Rev. 85, 423-493 (2005).
248. Ellison, D. H. The thiazide-sensitive Na-Cl cotransporter and human disease: Reemergence of an old player. J. Am. Soc. Nephrol. 14, 538-540 (2003).
249. - cotransporter. Am. J. Physiol. Renal. Physiol. 280, F574-582 (2001).
250. Kleyman, T. R., Sheng, S., Kosari, F. & Kieber-Emmons, T. Mechanism of action of amiloride: A molecular prospective. Semin. Nephrol. 19, 524-532 (1999).
251. + channel. J. Biol. Chem. 272, 21075-21083 (1997).
252. Priewer, H. & Ullrich, F. Potassium and magnesium retaining triamterene derivatives. Pharmazie 52, 179-181 (1997).
253. Eckstein-Ludwig, U. et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957-961 (2003).
254. Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. Nature Rev. Drug Discov. 2, 132-139 (2003).
255. Paula, S., Tabet, M. R. & Ball, W. J. Jr. Interactions between cardiac glycosides and sodium/potassium-ATPase: Three-dimensional structure-activity relationship models for ligand binding to the E2-Pi form of the enzyme versus activity inhibition. Biochemistry 44, 498-510 (2005).
256. Garcia-Calvo, M. et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).Proc. Natl Acad. Sci. USA 102, 8132-8137 (2005).
257. Goldberg, N. R., Beuming, T., Sayer, O. S., Goldstein, R, A., Weinstein, H. & Javitch, J. A. Probing conformational changes in neurotransmitter transporters: A structural context. Eur. J. Pharmacol. 479, 3-12 (2003).
258. Saier, Jr., M. H. A functional-phylogenetic system for the classification of transport proteins. J. Cell Biochem. Suppl. 32-33, 84-94 (1999).
259. Owens, M. J., Morgan, W. N., Platt, S. J. & Nemeroff, C. B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305-1322 (1997).
260. Blakely, R. D., De Felice, L. J. & Hartzell, H. C. Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196, 263-281 (1994).
261. Bondarev, M. L., Bondareva, T. S., Young, R. & Glennon, R. A. Behavioral and biochemical investigations of bupropion metabolites. Eur. J. Pharmacol. 474, 85-93 (2003).
262. Beique, J. C., Lavoie, N., de Montigny, C. & Debonnel, G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur. J. Pharmacol. 349, 129-132 (1998).
263. Henry, J. P. et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 196, 251-262 (1994).
264. Deupree, J. D. & Weaver, J. A Identification and characterization of the catecholamine ransporter in bovine chromaffin granules using [3H]reserpine. J. Biol. Chem. 259, 10907-10912 (1984).
265. Dervan, P. B. Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. 9, 2215-2235 (2001).
266. Mattes, W. B., Hartley, J. A. & Kohn, K. W. DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res. 14, 2971-2987 (1986).
267. Maccubbin, A. E., Caballes, L., Scappaticci, F., Struck, R. F. & Gurtoo, H. L. 32P-postlabeling analysis of binding of the cyclophosphamide metabolite, acrolein, to DNA. Cancer Commun. 2. 207-211 (1990).
268. Sanada, M., Takagi, Y., Ito, R. & Sekiguchi, M. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: Effects of Mgmt and Mlh1 mutations. DNA Repair (Amst.) 3, 413-420 (2004).
269. Delalande, O., Malina, J., Brabec, V. & Kozelka, J. Chiral differentiation of DNA adducts formed by enantiomeric analogues of antitumor cisplatin is sequence-dependent. Biophys J. 88, 4159-4169 (2005).
270. Siddik, Z. H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
271. Temperini, C. et al. The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. Nucleic Acids Res. 31, 1464-1469 (2003).
272. Hecht, S. M. Bleomycin: New perspectives on the mechanism of action. J. Nat. Prod. 63, 158-168 (2000).
273. Lamp, K. C., Freeman, C. D., Klutman, N. E. & Lacy, M. K. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 36, 353-373 (1999).
274. Carter, A. P. et al. Functional insights from the structure of the 308 ribosomal subunit and its interactions with antibiotics. Nature 407, 340-348 (2000).
275. Schlunzen, F. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814-821 (2001).
276. Colca, J. R. etal. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 278, 21972-21979 (2003).
277. Duflos, A., Kruczynski, A., Barret, J. M. Novel aspects of natural and modified vinca alkaloids. Curr. Med. Chem. Anti-Canc. Agents 2, 55-70 (2002).
278. Lipp, H. P. & Bokemeyer, C. The action and toxicity oftaxanes. Pharm. Unserer Zeit 34, 128-137 (2005).
279. Molad, Y. Update on colchicine and its mechanism of action. Curr. Rheumatol. Rep. 4, 252-256 (2002).
280. Hermann, T Drugs targeting the ribosome. Curr. Opin. Struct. Biol. 15, 355-366 (2005).
281. Anokhina, M. M., Barta, A., Nierhaus, K. H., Spiridonova, V. A. & Kopylov, A. M. Mapping of the second tetracycline binding site on the ribosomal small subunit of E. coli. Nucleic Acids Res. 32, 2594-2597 (2004).
282. Spizek, J., Navotna, J. & Rezanka, T. Lincosamides: Chemical structure, biosynthesis, mechanism ofaction, resistance, and applications. Adv. Appl. Microbiol. 56, 121-154 (2004).
283. Harms, J. M., Schlunzen, F., Fucini, P., Bartels, H. & Yonath, A. Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol. 2, 4 (2004).
284. Nygren, P., Sorbye, H., Osterlund, P. & Pfeiffer, P. targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab. Acta Oncol. 44, 203-217 (2005).
285. Muhsin, M., Graham, J. & Kirkpatrick, P. Bevacizumab. Nature Rev. Drug Discov. 3, 995-996 (2004).
286. Marecki, S. & Kirkpatrick, P. Efalizumab. Nature Rev. Drug Discov. 3, 473-474 (2004).
287. Goldberg, R. M. Cetuximab. Nature Rev. Drug Discov. 4, S10-S11 (2005).
288. Albanell, J., Codony, J., Rovira, A., Mellado, B. & Gascon, P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532, 253-268 (2003).
289. Davis, L. A. Omalizumab: A novel therapy for allergic asthma. Ann. Pharmacother. 38, 1236-1242 (2004).
290. Hooks, M. A., Wade, C. S. & Millikan, W. J., Jr, Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11, 26-37 (1991).
291. Witzig, T. E. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc.) 40, 111-119 (2004).
292. Multani, P. & White, C. A. Rituximab. Cancer Chemother. Biol. Response Modif. 21, 235-258 (2003).
293. Linenberger, M. L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19, 176-182 (2005).
294. Frampton, J. E. & Wagstaff, A. J. Alemtuzumab. Drugs 63, 1229-1243 (2003).
295. Scott, L. J. & Lamb, H. M. Palivizumab. Drugs 58, 305-313 (1999).
296. Kapic, E., Becic, F. & Kusturica, J. Basiliximab, mechanism of action and pharmacological properties. Med. Arh. 58, 373-376 (2004).
297. Carswell, C. I., Plosker, G. L. & Wagstaff, A. J. Daclizumab: A review of its use in the management of organ transplantation. BioDrugs 15, 745-773 (2001).
298. Bain, B. & Brazil, M. Adalimumab. Nature Rev. Drug Discov. 2, 693-694 (2003).
299. Winterfield, L. S. & Menter, A. Infliximab. Dermatol. Ther. 17, 409-426 (2004).
300. Faulds, D. & Sorkin, E. M. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 48, 583-598 (1994).
301. Noseworthy, J. H. & Kirkpatrick, P. Natalizumab. Nature Rev. Drug Discov. 4, 101-102 (2005).